Skip Nav Destination
Issues
15 August 2008
-
Cover Image
Cover Image
The biological applications of carbon nanotubes are very promising. Much progress has been made in using this novel material for molecular delivery in vitro. The current work of Liu and colleagues demonstrates the first carbon nanotube drug delivery for in vivo cancer treatment with animal models. Paclitaxel (PTX), a commonly used chemotherapy drug, is conjugated to short, single-walled carbon nanotubes (SWNT) functionalized by branched polyethylene glycol (PEG) via a cleavable ester bond, affording a water soluble, biocompatible SWNT-PTX conjugate (bottom panel). Intravenously injected SWNT-PTX exhibits higher efficacy in suppressing tumor growth than clinical Taxol® in a murine 4T1 breast-cancer model, owing to prolonged blood circulation and 10-fold higher tumor PTX uptake by SWNT delivery through the enhanced permeability and retention (EPR) effect. The cover figure upper panels compare the apoptosis levels of tumor cells after receiving various treatments including Taxol® and SWN-PTX. Higher apoptosis level and reduced cell proliferation is seen in the SWNT-PTX case. Drug molecules carried into the reticuloendothelial system are released from SWNTs and excreted via biliary pathway without causing obvious toxic effects to normal organs. Without attached drugs, PEG functionalized SWNTs are nontoxic to large numbers of injected mice. Thus, nanotube drug delivery is promising for high treatment efficacy and minimum side effects for future cancer therapy using low drug doses. Further work will focus on the optimization of SWNT surface chemistry and incorporation of targeting ligands for nanotube-based drug delivery systems. Much improved treatment efficacy and further reduced side effects are expected for a wide range of chemotherapy drugs. For details, see the article by Liu et al. on page 6652 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 0008-5472
EISSN 1538-7445
Journal Archive
Cancer Research (1941-Present; volumes 1-current)
(ISSN 0008-5472) Published twice monthly since 1987. From 1941-1986, published monthly.The American Journal of Cancer (1931-1940; volumes 15-40)
(ISSN 0099-7374) Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.The Journal of Cancer Research (1916-1930); volumes 1-14)
(ISSN 0099-7013) Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.Table of Contents
Reviews
Priority Reports
Variants in the ATM Gene Associated with a Reduced Risk of Contralateral Breast Cancer
Patrick Concannon; Robert W. Haile; Anne-Lise Børresen-Dale; Barry S. Rosenstein; Richard A. Gatti; Sharon N. Teraoka; Anh T. Diep; Laila Jansen; David P. Atencio; Bryan Langholz; Marinela Capanu; Xiaolin Liang; Colin B. Begg; Duncan C. Thomas; Leslie Bernstein; Jørgen H. Olsen; Kathleen E. Malone; Charles F. Lynch; Hoda Anton-Culver; Jonine L. Bernstein; for the Women's Environment, Cancer, and Radiation Epidemiology Study Collaborative Group
Cell, Tumor, and Stem Cell Biology
Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
Christian R. Schnell; Frédéric Stauffer; Peter R. Allegrini; Terence O'Reilly; Paul M.J. McSheehy; Celine Dartois; Michael Stumm; Robert Cozens; Amanda Littlewood-Evans; Carlos García-Echeverría; Sauveur-Michel Maira
Clinical Research
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Sensitization to the Lysosomal Cell Death Pathway by Oncogene-Induced Down-regulation of Lysosome-Associated Membrane Proteins 1 and 2
Nicole Fehrenbacher; Lone Bastholm; Thomas Kirkegaard-Sørensen; Bo Rafn; Trine Bøttzauw; Christina Nielsen; Ekkehard Weber; Senji Shirasawa; Tuula Kallunki; Marja Jäättelä
CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
David Krige; Lindsey A. Needham; Lindsay J. Bawden; Nicolas Flores; Hannah Farmer; Lauren E.C. Miles; Erica Stone; Juliana Callaghan; Stephen Chandler; Vanessa L. Clark; Patricia Kirwin-Jones; Valérie Legris; Jo Owen; Thakor Patel; Steve Wood; Gary Box; David Laber; Rajesh Odedra; Annette Wright; L. Michael Wood; Suzanne A. Eccles; Elisabeth A. Bone; Andrew Ayscough; Alan H. Drummond
Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo
Yihong Zhang; Paula J. Kaplan-Lefko; Karen Rex; Yajing Yang; Jodi Moriguchi; Tao Osgood; Bethany Mattson; Angela Coxon; Monica Reese; Tae-Seong Kim; Jasmine Lin; April Chen; Teresa L. Burgess; Isabelle Dussault
Inhibition of the Sodium/Potassium ATPase Impairs N-Glycan Expression and Function
Reza Beheshti Zavareh; Ken S. Lau; Rose Hurren; Alessandro Datti; David J. Ashline; Marcela Gronda; Pam Cheung; Craig D. Simpson; Wei Liu; Amanda R. Wasylishen; Paul C. Boutros; Hui Shi; Amudha Vengopal; Igor Jurisica; Linda Z. Penn; Vern N. Reinhold; Shereen Ezzat; Jeff Wrana; David R. Rose; Harry Schachter; James W. Dennis; Aaron D. Schimmer
A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin
Karen Liby; Mark M. Yore; Bill D. Roebuck; Karen J. Baumgartner; Tadashi Honda; Chitra Sundararajan; Hidenori Yoshizawa; Gordon W. Gribble; Charlotte R. Williams; Renee Risingsong; Darlene B. Royce; Albena T. Dinkova-Kostova; Katherine K. Stephenson; Patricia A. Egner; Melinda S. Yates; John D. Groopman; Thomas W. Kensler; Michael B. Sporn
Immunology
Molecular Biology, Pathobiology, and Genetics
Leptin Enhances Cholangiocarcinoma Cell Growth
Giammarco Fava; Gianfranco Alpini; Chiara Rychlicki; Stefania Saccomanno; Sharon DeMorrow; Luciano Trozzi; Cinzia Candelaresi; Julie Venter; Antonio Di Sario; Marco Marzioni; Italo Bearzi; Shannon Glaser; Domenico Alvaro; Luca Marucci; Heather Francis; Gianluca Svegliati-Baroni; Antonio Benedetti
The Nuclear Factor-κB Pathway Controls the Progression of Prostate Cancer to Androgen-Independent Growth
Ren Jie Jin; Yongsoo Lho; Linda Connelly; Yongqing Wang; Xiuping Yu; Leshana Saint Jean; Thomas C. Case; Katharine Ellwood-Yen; Charles L. Sawyers; Neil A. Bhowmick; Timothy S. Blackwell; Fiona E. Yull; Robert J. Matusik
Loss of the CBX7 Gene Expression Correlates with a Highly Malignant Phenotype in Thyroid Cancer
Pierlorenzo Pallante; Antonella Federico; Maria Teresa Berlingieri; Mimma Bianco; Angelo Ferraro; Floriana Forzati; Antonino Iaccarino; Maria Russo; Giovanna Maria Pierantoni; Vincenza Leone; Silvana Sacchetti; Giancarlo Troncone; Massimo Santoro; Alfredo Fusco
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Derek Y. Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C. LeBlanc; Diana J. Donovan; Swan N. Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H. Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H. Ligon; Vesna Najfeld; Scott L. Friedman; William R. Sellers; Matthew Meyerson; Josep M. Llovet
Prevention
Tumor Microenvironment
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3α and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions
Nicola Giuliani; Gina Lisignoli; Simona Colla; Mirca Lazzaretti; Paola Storti; Cristina Mancini; Sabrina Bonomini; Cristina Manferdini; Katia Codeluppi; Andrea Facchini; Vittorio Rizzoli
Corrections
Advertisement